Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Molecular basis for the thermostability of Newcastle disease virus.

Wen G, Hu X, Zhao K, Wang H, Zhang Z, Zhang T, Yang J, Luo Q, Zhang R, Pan Z, Shao H, Yu Q.

Sci Rep. 2016 Mar 3;6:22492. doi: 10.1038/srep22492.

2.

Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries.

Kristensen DD, Lorenson T, Bartholomew K, Villadiego S.

Vaccine. 2016 Feb 10;34(7):899-904. doi: 10.1016/j.vaccine.2016.01.001. Epub 2016 Jan 8.

3.

Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in Dissolving Microneedle Patches.

Chu LY, Ye L, Dong K, Compans RW, Yang C, Prausnitz MR.

Pharm Res. 2016 Apr;33(4):868-78. doi: 10.1007/s11095-015-1833-9. Epub 2015 Dec 1.

PMID:
26620313
4.
5.

Factors associated with the exposure of vaccines to adverse temperature conditions: the case of North West region, Cameroon.

Yakum MN, Ateudjieu J, PĂ©lagie FR, Walter EA, Watcho P.

BMC Res Notes. 2015 Jun 30;8:277. doi: 10.1186/s13104-015-1257-y.

6.

Vaccine storage and cold chain monitoring in the North West region of Cameroon: a cross sectional study.

Yakum MN, Ateudjieu J, Walter EA, Watcho P.

BMC Res Notes. 2015 Apr 14;8:145. doi: 10.1186/s13104-015-1109-9.

7.

A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact.

Jonsson-Schmunk K, Croyle MA.

Expert Rev Anti Infect Ther. 2015 May;13(5):527-30. doi: 10.1586/14787210.2015.1028368. Epub 2015 Mar 23.

8.

A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.

Li X, Thakkar SG, Ruwona TB, Williams RO 3rd, Cui Z.

J Control Release. 2015 Apr 28;204:38-50. doi: 10.1016/j.jconrel.2015.02.035. Epub 2015 Feb 28. Erratum in: J Control Release. 2015 Jul 10;209:197.

9.

Advances in aluminum hydroxide-based adjuvant research and its mechanism.

He P, Zou Y, Hu Z.

Hum Vaccin Immunother. 2015;11(2):477-88. doi: 10.1080/21645515.2014.1004026. Review.

10.

A freeze-stable formulation for DTwP and DTaP vaccines.

Xue H, Yang B, Kristensen DD, Chen D.

Hum Vaccin Immunother. 2014;10(12):3607-10. doi: 10.4161/21645515.2014.980195.

11.

Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.

Hassett KJ, Vance DJ, Jain NK, Sahni N, Rabia LA, Cousins MC, Joshi S, Volkin DB, Middaugh CR, Mantis NJ, Carpenter JF, Randolph TW.

J Pharm Sci. 2015 Feb;104(2):627-39. doi: 10.1002/jps.24295. Epub 2015 Jan 11.

12.

Reducing the loss of vaccines from accidental freezing in the cold chain: the experience of continuous temperature monitoring in Tunisia.

Lloyd J, Lydon P, Ouhichi R, Zaffran M.

Vaccine. 2015 Feb 11;33(7):902-7. doi: 10.1016/j.vaccine.2014.10.080. Epub 2014 Nov 8.

13.

Vaccination management and vaccination errors: a representative online-survey among primary care physicians.

Weltermann BM, Markic M, Thielmann A, Gesenhues S, Hermann M.

PLoS One. 2014 Aug 13;9(8):e105119. doi: 10.1371/journal.pone.0105119. eCollection 2014.

14.

Carbohydrate-based ice recrystallization inhibitors increase infectivity and thermostability of viral vectors.

Ghobadloo SM, Balcerzak AK, Gargaun A, Muharemagic D, Mironov GG, Capicciotti CJ, Briard JG, Ben RN, Berezovski MV.

Sci Rep. 2014 Jul 31;4:5903. doi: 10.1038/srep05903.

15.

Tools and approaches to ensure quality of vaccines throughout the cold chain.

Kartoglu U, Milstien J.

Expert Rev Vaccines. 2014 Jul;13(7):843-54. doi: 10.1586/14760584.2014.923761. Epub 2014 May 28. Review.

16.

Frequent exposure to suboptimal temperatures in vaccine cold-chain system in India: results of temperature monitoring in 10 states.

Murhekar MV, Dutta S, Kapoor AN, Bitragunta S, Dodum R, Ghosh P, Swamy KK, Mukhopadhyay K, Ningombam S, Parmar K, Ravishankar D, Singh B, Singh V, Sisodiya R, Subramanian R, Takum T.

Bull World Health Organ. 2013 Dec 1;91(12):906-13. doi: 10.2471/BLT.13.119974. Epub 2013 Sep 9.

17.

Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.

Hassett KJ, Cousins MC, Rabia LA, Chadwick CM, O'Hara JM, Nandi P, Brey RN, Mantis NJ, Carpenter JF, Randolph TW.

Eur J Pharm Biopharm. 2013 Oct;85(2):279-86. doi: 10.1016/j.ejpb.2013.03.029. Epub 2013 Apr 10.

18.

Program on immunization and cold chain monitoring: the status in eight health districts in Cameroon.

Ateudjieu J, Kenfack B, Nkontchou BW, Demanou M.

BMC Res Notes. 2013 Mar 16;6:101. doi: 10.1186/1756-0500-6-101.

19.

Vaccine Presentation and Packaging Advisory Group: a forum for reaching consensus on vaccine product attributes.

Mansoor OD, Kristensen D, Meek A, Zipursky S, Popova O, Sharma I, Miranda G, Millogo J, Lasher H.

Bull World Health Organ. 2013 Jan 1;91(1):75-8. doi: 10.2471/BLT.12.110700. Epub 2012 Nov 5. No abstract available. Erratum in: Bull World Health Organ. 2013 Feb 1;91(2):156. Popovaa, Olga [corrected to Popova, Olga].

20.

Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine.

Garcia CR, Manzi F, Tediosi F, Hoffman SL, James ER.

Vaccine. 2013 Jan 2;31(2):380-6. doi: 10.1016/j.vaccine.2012.10.109. Epub 2012 Nov 10.

Items per page

Supplemental Content

Write to the Help Desk